New York, NY, United States of America

Lydia Finley

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Memorial Sloan Kettering Cancer Center. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lydia Finley. Retrieved from https://idiyas.com/inventor/lydia-finley

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 


Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Lydia Finley: Cancer Research and Patent Innovation.

Introduction

Lydia Finley is an inventor associated with Memorial Sloan Kettering Cancer Center in New York, NY. Her patent work concerns a potential approach to treating cancers with mutations in the p53 gene.

Latest Patents

Finley is listed as an inventor on 1 patent: “Methods of Treating P53 Mutant Cancers Using OGDH Inhibitors.” The patent describes the use of OGDH inhibitors as a proposed treatment strategy for p53-mutant cancers.

Career Highlights

Finley’s listed invention reflects research focused on cancer biology and therapeutic development. Her work is associated with Memorial Sloan Kettering Cancer Center, a research institution in New York.

Collaborations

The provided information lists Scott Lowe and Scott E. Millman among Finley’s coworkers. Their names indicate professional connections, but the available details do not specify their roles in the patent or related research.

Conclusion

Lydia Finley’s patent activity highlights an invention exploring OGDH inhibitors as a potential treatment approach for p53-mutant cancers.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…